Ultimovacs ASA Total Liabilities
Ultimovacs ASA total liabilities. Based on the latest financial reports, Ultimovacs ASA (ULTI) has total liabilities worth Nkr33.19 Million NOK (≈ $3.49 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ULTI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ultimovacs ASA (2016–2024)
Total liabilities of Ultimovacs ASA from 2016 to 2024. This chart illustrates how Ultimovacs ASA's total liabilities have evolved over time, based on quarterly financial data.
Ultimovacs ASA Competitors by Total Liabilities
The table below lists competitors of Ultimovacs ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BE Group AB
ST:BEGR
|
Sweden | Skr1.22 Billion |
|
Skyharbour Resources Ltd
V:SYH
|
Canada | CA$503.11K |
|
Lunnon Metals Ltd
AU:LM8
|
Australia | AU$1.16 Million |
|
Hankook Furniture Co. Ltd
KQ:004590
|
Korea | ₩52.62 Billion |
|
Hae In
KO:003010
|
Korea | ₩125.75 Billion |
|
Imago Mulia Persada Tbk PT
JK:LFLO
|
Indonesia | Rp99.34 Billion |
|
THINKWARE Corporation
KQ:084730
|
Korea | ₩192.78 Billion |
|
Societe de Tayninh SA
PA:TAYN
|
France | €86.44K |
Liability Composition Analysis (2016–2024)
This chart breaks down Ultimovacs ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ultimovacs ASA (ULTI) total assets.
Liquidity & Leverage Metrics
Ultimovacs ASA Total Liabilities Ratios Explained
Ultimovacs ASA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ultimovacs ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ultimovacs ASA (2016–2024)
The table below shows the annual total liabilities of Ultimovacs ASA from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr33.19 Million ≈ $3.49 Million |
-52.34% |
| 2023-12-31 | Nkr69.65 Million ≈ $7.33 Million |
+15.46% |
| 2022-12-31 | Nkr60.32 Million ≈ $6.35 Million |
-3.31% |
| 2021-12-31 | Nkr62.38 Million ≈ $6.56 Million |
+50.92% |
| 2020-12-31 | Nkr41.34 Million ≈ $4.35 Million |
+23.73% |
| 2019-12-31 | Nkr33.41 Million ≈ $3.52 Million |
+11.53% |
| 2018-12-31 | Nkr29.96 Million ≈ $3.15 Million |
+142.66% |
| 2017-12-31 | Nkr12.35 Million ≈ $1.30 Million |
+81.36% |
| 2016-12-31 | Nkr6.81 Million ≈ $716.29K |
-- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.